12:02:25 EDT Fri 03 May 2024
Enter Symbol
or Name
USA
CA



E:CYBN - CYBIN INC. - http://www.cybin.com
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
CYBN - E  11.50.48·0.48521.00.485+0.0051.0171.5771450.48  0.49  0.47750.98  0.3011:10:02Apr 2515 min RT 2¢
NEO exchange - E11.50.48·0.48521.00.485+0.0051.0137.062850.48  0.49  0.47750.98  0.3011:10:0215 min
Omega - O 0.481.0020.48  0.48  0.4810:34:3015 min
Chi-X - X 0.485+0.0051.07.03120.485  0.49  0.477510:42:2915 min
CX2 - H 0.485+0.0051.01.0020.485  0.485  0.48510:42:2915 min
CXD - D 0.480.909    Apr 2915 min
TriAct - M 0.4824.61135    15 min

Recent Trades - Last 10 of 145
Time ETExPriceChangeVolumeBuyerSellerMarkers
11:43:58M0.4850.0055080 National Bank80 National BankE
11:34:36M0.48 14180 National Bank80 National BankE
11:22:40M0.48 5085 Scotia85 ScotiaE
11:19:07M0.4850.0054004 Cantor Fitz14 Virtu ITGE
11:10:02E0.4850.0051,00084 ITG841 AnonymousK
11:09:55E0.48250.00251,00084 ITG841 AnonymousK
11:06:00M0.4850.005680 National Bank80 National BankE
11:00:09E0.4850.0052,50080 National Bank1 AnonymousK
10:59:03M0.4850.00527 TD Sec14 Virtu ITGE
10:57:32E0.48250.002510,000124 Questrade1 AnonymousK

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolPriceTypeHeadline
2024-04-18 13:00C:CYBN0.51News ReleaseCybin publishes CYB210010 research manuscript
2024-04-16 12:27C:CYBN0.51News ReleaseCybin receives depressive disorder therapy patent
2024-04-08 07:12C:CYBN0.55In the NewsGlobe says MindMed, Cybin get nod from U.S. FDA
2024-03-19 12:42C:CYBN0.61News ReleaseCybin closes $150-million (U.S.) private placement
2024-03-15 09:12C:CYBN0.61News ReleaseCybin begins phase 2 CYB004 study for GAD treatment
2024-03-14 11:30C:CYBN0.58News ReleaseCybin talks CYB003 phase 2 FDA meeting, phase 3 design
2024-03-13 09:16C:CYBN0.58News ReleaseCybin arranges $150-million (U.S.) private placement
2024-03-13 08:59C:CYBN0.57News ReleaseCybin's CYB003 receives FDA breakthrough designation
2024-03-12 23:17C:CYBN0.58News ReleaseCybin to host call March 13 for CYB003 update
2024-02-14 12:40C:CYBN0.475News ReleaseCybin has cash of $39-million at Dec. 31
2024-02-14 07:40C:CYBN0.475SEDAR Interim MD & ASEDAR Interim MD & A
2024-02-14 07:34C:CYBN0.475SEDAR Interim Financial StatementsSEDAR Interim Financial Statements
2024-02-07 11:55C:CYBN0.395News ReleaseCybin receives two patents in Japan for DMT program
2024-01-23 09:05C:CYBN0.485News ReleaseCybin receives FDA OK to begin phase 2a CYB004 study
2024-01-08 11:46C:CYBN0.54News ReleaseCybin says CYB004, SPL028 well tolerated in phase 1
2024-01-04 10:54C:CYBN0.52News ReleaseCybin outlines phase 2 CYB003 results in MDD
2023-12-06 10:41C:CYBN0.57News ReleaseCybin receives U.S. patent for CYB003 program
2023-11-30 10:34C:CYBN0.64News ReleaseCybin boasts about CYB003 phase 2 safety, efficacy data
2023-11-16 12:46C:CYBN0.60News ReleaseCybin to release phase 2 CYB003 data Nov. 30
2023-11-14 19:32C:CYBN0.62News ReleaseCybin has cash of $18.1-million at Sept. 30